Journal of Vascular and Interventional Radiology
Volume 20, Issue 1 , Pages 17-21 , January 2009

Clinical Experience with the Use of Bivalirudin in a Large Population Undergoing Endovascular Abdominal Aortic Aneurysm Repair

  • Sarah Stamler, BA

      Affiliations

    • University of Miami Miller School of Medicine, Baptist Cardiac and Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176
    • ,
  • Barry T. Katzen, MD

      Affiliations

    • Division of Vascular Surgery, Baptist Cardiac and Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176
    • Corresponding Author InformationAddress correspondence to B.T.K.
    • ,
  • Athanassios I. Tsoukas, MD

      Affiliations

    • Division of Vascular Surgery, Baptist Cardiac and Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176
    • ,
  • Samuel Z. Baum

      Affiliations

    • Division of Vascular Surgery, Baptist Cardiac and Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176
    • ,
  • Nicolas Diehm, MD

      Affiliations

    • Division of Vascular Surgery, Baptist Cardiac and Vascular Institute, 8900 North Kendall Drive, Miami, FL 33176
    • Division of Clinical and Interventional Angiology and Vascular Research, Swiss Cardiovascular Center, Inselspital, University Hospital, Bern, Switzerland

Received 18 March 2008 ,Revised 25 September 2008 ,Accepted 28 September 2008.

References 

  1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188–203
  2. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311–337
  3. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703–1708
  4. Ahrens I, Smith BK, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. Expert Opin Drug Metab Toxicol. 2007;3:609–620
  5. Weitz JI, Crowther MA. New anticoagulants: current status and future potential. Am J Cardiovasc Drugs. 2003;3:201–209
  6. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105–111
  7. Singh S, Molnar J, Arora R. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovasc Pharmacol Ther. 2007;12:283–291
  8. MacLean AA, Pena CS, Katzen BT. Bivalirudin in peripheral interventions. Tech Vasc Interv Radiol. 2006;9:80–83
  9. Katzen BT, Ardid MI, MacLean AA, et al. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vasc Interv Radiol. 2005;16:1183–1187
  10. Allie DE, Lirtzman MD, Wyatt CH, et al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invas Cardiol. 2003;15:334–342
  11. Allie DE, Hall P, Shammas NW, et al. The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results. J Invas Cardiol. 2004;16:651–656
  12. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991;5:491–499
  13. Katzen BT, Dake MD, MacLean AA, Wang DS. Endovascular repair of abdominal and thoracic aortic aneurysms. Circulation. 2005;112:1663–1675
  14. Moore WS, Matsumura JS, Makaroun MS, et al. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. J Vasc Surg. 2003;38:46–55
  15. Faries PL, Brener BJ, Connelly TL, et al. A multicenter experience with the Talent endovascular graft for the treatment of abdominal aortic aneurysms. J Vasc Surg. 2002;35:1123–1128
  16. Najibi S, Steinberg J, Katzen BT, et al. Detection of isolated hook fractures 36 months after implantation of the Ancure endograft: a cautionary note. J Vasc Surg. 2001;34:353–356
  17. Matsumura JS, Katzen BT, Hollier LH, Dake MD. Update on the bifurcated Excluder endoprosthesis: phase I results. J Vasc Surg. 2001;33:150–153
  18. Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg. 2002;35:1048–1060
  19. Suggested standards for reports dealing with lower extremity ischemia (Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery). J Vasc Surg. 1986;4:80–94
  20. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  21. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105:453–463
  22. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391
  23. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533–539
  24. Smedira NG, Dyke CM, Koster A, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686–692
  25. Shammas NW, Allie D, Hall P, et al. Predictors of in-hospital and 30-day complications of peripheral vascular interventions using bivalirudin as the primary anticoagulant: results from the APPROVE registry. J Invas Cardiol. 2005;17:356–359
  26. Allie DE, Hebert CJ, Lirtzman MD, et al. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invas Cardiol. 2005;17:427–432

 None of the authors have identified a conflict of interest.

PII: S1051-0443(08)00889-0

doi: 10.1016/j.jvir.2008.09.031

Journal of Vascular and Interventional Radiology
Volume 20, Issue 1 , Pages 17-21 , January 2009

Article Tools